Published in Eur J Med Chem on October 01, 2002
Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction. J Virol (2006) 1.71
A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma. Invest New Drugs (2007) 1.09
Herpes simplex virus type 2 glycoprotein G is targeted by the sulfated oligo- and polysaccharide inhibitors of virus attachment to cells. J Virol (2007) 0.84
Synthesis, separation, and characterization of amphiphilic sulfated oligosaccharides enabled by reversed-phase ion pairing LC and LC-MS methods. Carbohydr Res (2011) 0.81
Anti-metastatic semi-synthetic sulfated maltotriose C-C linked dimers. Synthesis and characterisation. Molecules (2012) 0.80
Bioengineered heparins and heparan sulfates. Adv Drug Deliv Rev (2015) 0.78
Inhibitors of slit protein interactions with the heparan sulphate proteoglycan glypican-1: potential agents for the treatment of spinal cord injury. Clin Exp Pharmacol Physiol (2009) 0.78
Carbohydrate-related inhibitors of dengue virus entry. Viruses (2013) 0.78
Mucin-like Region of Herpes Simplex Virus Type 1 Attachment Protein Glycoprotein C (gC) Modulates the Virus-Glycosaminoglycan Interaction. J Biol Chem (2015) 0.77
Heparin-protein interactions. Angew Chem Int Ed Engl (2002) 7.27
Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol (2008) 4.46
Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol (2007) 3.73
Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem (2003) 2.94
Lessons learned from the contamination of heparin. Nat Prod Rep (2009) 2.81
Chemoenzymatic synthesis of homogeneous ultralow molecular weight heparins. Science (2011) 2.79
A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med (2013) 2.68
Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology (2005) 2.46
The proteoglycan bikunin has a defined sequence. Nat Chem Biol (2011) 2.14
Role of glycosaminoglycans in cellular communication. Acc Chem Res (2004) 2.14
Structural basis by which alternative splicing modulates the organizer activity of FGF8 in the brain. Genes Dev (2005) 2.10
Solution structures of chemoenzymatically synthesized heparin and its precursors. J Am Chem Soc (2008) 2.02
Flexible energy storage devices based on nanocomposite paper. Proc Natl Acad Sci U S A (2007) 2.02
Biochemical analysis of pathogenic ligand-dependent FGFR2 mutations suggests distinct pathophysiological mechanisms for craniofacial and limb abnormalities. Hum Mol Genet (2004) 1.92
Electron detachment dissociation of glycosaminoglycan tetrasaccharides. J Am Soc Mass Spectrom (2006) 1.89
Enzymatic redesigning of biologically active heparan sulfate. J Biol Chem (2005) 1.89
Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction. J Virol (2006) 1.71
Heparin-binding domains in vascular biology. Arterioscler Thromb Vasc Biol (2004) 1.71
Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity. Proc Natl Acad Sci U S A (2004) 1.70
Proline to arginine mutations in FGF receptors 1 and 3 result in Pfeiffer and Muenke craniosynostosis syndromes through enhancement of FGF binding affinity. Hum Mol Genet (2003) 1.66
Further removal of factor v related antigen from bovine thrombin by utilizing a membrane-filtration step. Clin Appl Thromb Hemost (2007) 1.66
E. coli K5 fermentation and the preparation of heparosan, a bioengineered heparin precursor. Biotechnol Bioeng (2010) 1.65
Chemoenzymatic design of heparan sulfate oligosaccharides. J Biol Chem (2010) 1.64
Distinguishing glucuronic from iduronic acid in glycosaminoglycan tetrasaccharides by using electron detachment dissociation. Anal Chem (2007) 1.61
Generic forms of low-molecular-weight heparins: some practical considerations. Clin Appl Thromb Hemost (2003) 1.53
Characterization of a heparan sulfate octasaccharide that binds to herpes simplex virus type 1 glycoprotein D. J Biol Chem (2002) 1.53
Liquid chromatography/mass spectrometry sequencing approach for highly sulfated heparin-derived oligosaccharides. J Biol Chem (2003) 1.51
Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications. Clin Appl Thromb Hemost (2006) 1.51
Effect of bosentan on plasma markers of endothelial cell activity in patients with secondary pulmonary hypertension related to connective tissue diseases. J Rheumatol (2009) 1.47
Glycomics of proteoglycan biosynthesis in murine embryonic stem cell differentiation. J Proteome Res (2007) 1.46
Warfarin-induced skin necrosis: a case report. Clin Appl Thromb Hemost (2006) 1.46
Ionic liquid-mediated selective extraction of lignin from wood leading to enhanced enzymatic cellulose hydrolysis. Biotechnol Bioeng (2009) 1.46
Quantification of heparan sulfate disaccharides using ion-pairing reversed-phase microflow high-performance liquid chromatography with electrospray ionization trap mass spectrometry. Anal Chem (2009) 1.45
Identification and characterization of a glycosaminoglycan recognition element of the C chemokine lymphotactin. J Biol Chem (2004) 1.42
Disaccharide analysis of glycosaminoglycan mixtures by ultra-high-performance liquid chromatography-mass spectrometry. J Chromatogr A (2011) 1.42
Structural analysis of the sulfotransferase (3-o-sulfotransferase isoform 3) involved in the biosynthesis of an entry receptor for herpes simplex virus 1. J Biol Chem (2004) 1.41
Electron detachment dissociation of dermatan sulfate oligosaccharides. J Am Soc Mass Spectrom (2007) 1.40
Influence of charge state and sodium cationization on the electron detachment dissociation and infrared multiphoton dissociation of glycosaminoglycan oligosaccharides. J Am Soc Mass Spectrom (2008) 1.40
Negative electron transfer dissociation of glycosaminoglycans. Anal Chem (2010) 1.39
Oral factor Xa and direct thrombin inhibitors: a clinical perspective. J Burn Care Res (2012) 1.38
Crystal structure and mutational analysis of heparan sulfate 3-O-sulfotransferase isoform 1. J Biol Chem (2004) 1.38
Toll-like receptor 4 mediates induction of the Bcl10-NFkappaB-interleukin-8 inflammatory pathway by carrageenan in human intestinal epithelial cells. J Biol Chem (2008) 1.38
Review: contaminants in heparin: review of the literature, molecular profiling, and clinical implications. Clin Appl Thromb Hemost (2011) 1.38
Structural analysis of bikunin glycosaminoglycan. J Am Chem Soc (2008) 1.37
Orthogonal analytical approaches to detect potential contaminants in heparin. Proc Natl Acad Sci U S A (2009) 1.36
Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost (2006) 1.35
Control of the heparosan N-deacetylation leads to an improved bioengineered heparin. Appl Microbiol Biotechnol (2011) 1.33
Kinetic model for FGF, FGFR, and proteoglycan signal transduction complex assembly. Biochemistry (2004) 1.33
Heparin accelerates gelsolin amyloidogenesis. Biochemistry (2006) 1.31
Room temperature ionic liquids as emerging solvents for the pretreatment of lignocellulosic biomass. Biotechnol Bioeng (2011) 1.31
Analysis of E. coli K5 capsular polysaccharide heparosan. Anal Bioanal Chem (2010) 1.30
Enzymatic synthesis of heparin related polysaccharides on sensor chips: rapid screening of heparin-protein interactions. Biochem Biophys Res Commun (2005) 1.29
Ultra-performance ion-pairing liquid chromatography with on-line electrospray ion trap mass spectrometry for heparin disaccharide analysis. Anal Biochem (2011) 1.28
Microscale isolation and analysis of heparin from plasma using an anion-exchange spin column. Anal Biochem (2006) 1.27
Top-down approach for the direct characterization of low molecular weight heparins using LC-FT-MS. Anal Chem (2012) 1.26
Proteoglycomics: recent progress and future challenges. OMICS (2010) 1.25
Recent chemical and enzymatic approaches to the synthesis of glycosaminoglycan oligosaccharides. Curr Med Chem (2003) 1.25
PI-88 and novel heparan sulfate mimetics inhibit angiogenesis. Semin Thromb Hemost (2007) 1.24
Heparin mapping using heparin lyases and the generation of a novel low molecular weight heparin. J Med Chem (2010) 1.24
Electron-induced dissociation of glycosaminoglycan tetrasaccharides. J Am Soc Mass Spectrom (2008) 1.23
The structure of chondroitin B lyase complexed with glycosaminoglycan oligosaccharides unravels a calcium-dependent catalytic machinery. J Biol Chem (2004) 1.23
Kinetic studies on the interactions of heparin and complement proteins using surface plasmon resonance. Biochim Biophys Acta (2005) 1.22
Using a 3-O-sulfated heparin octasaccharide to inhibit the entry of herpes simplex virus type 1. Biochemistry (2008) 1.21
MicroRNAs regulate tumor angiogenesis modulated by endothelial progenitor cells. Cancer Res (2012) 1.21
Identification of the capsular polysaccharides of Type D and F Pasteurella multocida as unmodified heparin and chondroitin, respectively. Carbohydr Res (2002) 1.20
Preparation of biopolymer fibers by electrospinning from room temperature ionic liquids. Biomacromolecules (2006) 1.19
Engineering of routes to heparin and related polysaccharides. Appl Microbiol Biotechnol (2011) 1.19
Structural characterization of human liver heparan sulfate. Biochim Biophys Acta (2004) 1.18
Analysis of pharmaceutical heparins and potential contaminants using (1)H-NMR and PAGE. J Pharm Sci (2009) 1.16
Proinflammatory cytokines in the prefrontal cortex of teenage suicide victims. J Psychiatr Res (2011) 1.16
Isolation and characterization of heparan sulfate from various murine tissues. Glycoconj J (2006) 1.15
Immobilization of heparin: approaches and applications. Curr Top Med Chem (2008) 1.14
High-resolution crystal structure of Arthrobacter aurescens chondroitin AC lyase: an enzyme-substrate complex defines the catalytic mechanism. J Mol Biol (2004) 1.14
Analysis of mutations in fibroblast growth factor (FGF) and a pathogenic mutation in FGF receptor (FGFR) provides direct evidence for the symmetric two-end model for FGFR dimerization. Mol Cell Biol (2005) 1.13
Synthesis of gold and silver nanoparticles stabilized with glycosaminoglycans having distinctive biological activities. Biomacromolecules (2009) 1.12
Oversulfated chondroitin sulfate interaction with heparin-binding proteins: new insights into adverse reactions from contaminated heparins. Biochem Pharmacol (2009) 1.12
Dissecting the substrate recognition of 3-O-sulfotransferase for the biosynthesis of anticoagulant heparin. Proc Natl Acad Sci U S A (2012) 1.11
Heparinase 1 selectivity for the 3,6-di-O-sulfo-2-deoxy-2-sulfamido-alpha-D-glucopyranose (1,4) 2-O-sulfo-alpha-L-idopyranosyluronic acid (GlcNS3S6S-IdoA2S) linkages. Glycobiology (2010) 1.11
Cell-bound IL-8 increases in bronchial epithelial cells after arylsulfatase B silencing due to sequestration with chondroitin-4-sulfate. Am J Respir Cell Mol Biol (2009) 1.11
Oversulfated chondroitin sulfate: impact of a heparin impurity, associated with adverse clinical events, on low-molecular-weight heparin preparation. J Med Chem (2008) 1.11
Ultraperformance liquid chromatography with electrospray ionization ion trap mass spectrometry for chondroitin disaccharide analysis. Anal Biochem (2009) 1.10
Complete mass spectral characterization of a synthetic ultralow-molecular-weight heparin using collision-induced dissociation. Anal Chem (2012) 1.10
Kinetic and structural studies on interactions between heparin or heparan sulfate and proteins of the hedgehog signaling pathway. Biochemistry (2007) 1.10
Chondroitin 6-sulphate synthesis is up-regulated in injured CNS, induced by injury-related cytokines and enhanced in axon-growth inhibitory glia. Eur J Neurosci (2005) 1.10
Recent progress and applications in glycosaminoglycan and heparin research. Curr Opin Chem Biol (2009) 1.10
HSulf-1 modulates FGF2- and hypoxia-mediated migration and invasion of breast cancer cells. Cancer Res (2011) 1.09